Market overview
The global nasal drug delivery market is worth USD 19.1 bn in 2026 and is forecast to reach USD 34.8 bn by 2036, growing at a 6.2% CAGR. United States is the largest country market and Sprays is the largest by dosage form segment.
| Scope | Nasal drug delivery products: sprays, powders, gels and devices delivering drugs through the nose for local and systemic effect. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 18.0 bn |
| Value 2026 | USD 19.1 bn |
| Value 2036 | USD 34.8 bn |
| CAGR 2026-2036 | 6.2% |
| Volume 2026 | 1,893 million units |
| Volume 2036 | 3,190 million units |
| Average price 2026 | USD 10.1 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Nasal Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 19.1 bn |
| 2027 | USD 20.3 bn |
| 2028 | USD 21.5 bn |
| 2029 | USD 22.9 bn |
| 2030 | USD 24.3 bn |
| 2031 | USD 25.8 bn |
| 2032 | USD 27.4 bn |
| 2033 | USD 29.1 bn |
| 2034 | USD 30.9 bn |
| 2035 | USD 32.8 bn |
| 2036 | USD 34.8 bn |
Nasal Drug Delivery market segmentation
By dosage form
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Sprays | 72.0% | 68.6% | USD 13.7 bn | 5.7% |
| Powders | 10.0% | 12.6% | USD 1.9 bn | 8.7% |
| Drops and gels | 12.0% | 10.9% | USD 2.3 bn | 5.2% |
| Other | 6.0% | 7.9% | USD 1.1 bn | 9.2% |
By use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Allergic rhinitis and congestion | 52.0% | 44.2% | USD 9.9 bn | 4.5% |
| Pain, migraine and CNS | 16.0% | 20.8% | USD 3.1 bn | 9.0% |
| Vaccines | 10.0% | 12.4% | USD 1.9 bn | 8.5% |
| Hormonal and other | 22.0% | 22.6% | USD 4.2 bn | 6.5% |
By drug class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Corticosteroids | 26.0% | 24.0% | USD 5.0 bn | 5.3% |
| Antihistamines | 18.0% | 16.0% | USD 3.4 bn | 5.0% |
| Decongestants | 14.0% | 12.0% | USD 2.7 bn | 4.6% |
| Peptides and hormones | 16.0% | 19.0% | USD 3.1 bn | 8.0% |
| Vaccines and CNS drugs | 26.0% | 29.0% | USD 5.0 bn | 7.4% |
By device
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Nasal sprays | 48.0% | 44.0% | USD 9.2 bn | 5.3% |
| Nasal powders and gels | 14.0% | 15.0% | USD 2.7 bn | 6.9% |
| Drops and instillation | 18.0% | 14.0% | USD 3.4 bn | 3.6% |
| Pressurized and atomizer devices | 20.0% | 27.0% | USD 3.8 bn | 9.4% |
By target
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Local action | 44.0% | 40.0% | USD 8.4 bn | 5.2% |
| Systemic action | 34.0% | 36.0% | USD 6.5 bn | 6.8% |
| Nose-to-brain delivery | 22.0% | 24.0% | USD 4.2 bn | 7.1% |
Top 25 countries for nasal drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 81.5% of 2026 revenue and the 25 countries below together hold 95.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 6.9 bn | 36.0% | USD 12.4 bn | 6.1% |
| 2 | China | USD 1.9 bn | 10.0% | USD 3.4 bn | 6.1% |
| 3 | Germany | USD 1.1 bn | 6.0% | USD 1.9 bn | 5.1% |
| 4 | Japan | USD 1.1 bn | 6.0% | USD 1.8 bn | 4.7% |
| 5 | India | USD 954 mn | 5.0% | USD 2.4 bn | 9.7% |
| 6 | France | USD 954 mn | 5.0% | USD 1.6 bn | 5.1% |
| 7 | United Kingdom | USD 763 mn | 4.0% | USD 1.3 bn | 5.7% |
| 8 | Brazil | USD 668 mn | 3.5% | USD 1.4 bn | 7.6% |
| 9 | Italy | USD 572 mn | 3.0% | USD 940 mn | 5.1% |
| 10 | Canada | USD 572 mn | 3.0% | USD 975 mn | 5.5% |
| 11 | Spain | USD 384 mn | 2.0% | USD 728 mn | 6.6% |
| 12 | Mexico | USD 321 mn | 1.7% | USD 609 mn | 6.6% |
| 13 | Australia | USD 301 mn | 1.6% | USD 571 mn | 6.6% |
| 14 | South Korea | USD 273 mn | 1.4% | USD 515 mn | 6.6% |
| 15 | Netherlands | USD 219 mn | 1.1% | USD 418 mn | 6.7% |
| 16 | Russia | USD 183 mn | 1.0% | USD 348 mn | 6.6% |
| 17 | Turkey | USD 174 mn | 0.9% | USD 327 mn | 6.5% |
| 18 | Poland | USD 145 mn | 0.8% | USD 275 mn | 6.6% |
| 19 | Sweden | USD 132 mn | 0.7% | USD 247 mn | 6.5% |
| 20 | Switzerland | USD 118 mn | 0.6% | USD 223 mn | 6.5% |
| 21 | Belgium | USD 95 mn | 0.5% | USD 181 mn | 6.6% |
| 22 | Argentina | USD 80 mn | 0.4% | USD 150 mn | 6.5% |
| 23 | Saudi Arabia | USD 72 mn | 0.4% | USD 136 mn | 6.5% |
| 24 | Indonesia | USD 61 mn | 0.3% | USD 115 mn | 6.5% |
| 25 | Taiwan | USD 57 mn | 0.3% | USD 108 mn | 6.5% |
| Rest of world | USD 914 mn | 4.8% | USD 1.7 bn | 6.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- GSK
- Sanofi
- Bayer
- Haleon
- Viatris
- Teva
- Organon
- AstraZeneca
Group 2: Regional and specialist players
- Aptar Pharma
- Gerresheimer
- Nemera
- Becton Dickinson
- Ursatec
- Lupin
- Glenmark
- Hikma
Group 3: Emerging and niche players
- Neurelis
- Bespak
- Amphastar Pharmaceuticals
- Orexo
- Nasus Pharma
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the nasal drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.2% is calculated from the resulting values.
The market is divided by dosage form, by use, by drug class, by device, by target. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the nasal drug delivery market?
The global nasal drug delivery market is estimated at USD 18.0 bn in 2025 and USD 19.1 bn in 2026.
How fast will the nasal drug delivery market grow?
It is forecast to reach USD 34.8 bn by 2036, a compound annual growth rate of 6.2% from 2026, an increase of USD 15.7 bn.
Which country is the largest market for nasal drug delivery?
United States is the largest market by revenue at USD 6.9 bn in 2026, 36.0% of the global total. The three largest countries together hold 52.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 9.7% a year from 2026 to 2036.
Which nasal drug delivery segment is largest?
In the by dosage form split, Sprays is the largest segment with 72.0% of 2026 revenue.
Who are the leading nasal drug delivery companies?
Global leaders include GSK, Sanofi, Bayer, Haleon.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Pharmaceutical GlassUSD 19.4 bn · 7.2% CAGR
- Injectable Drug DeliveryUSD 19.6 bn · 9.0% CAGR
- Medical BillingUSD 20.0 bn · 11.0% CAGR
- NanomedicineUSD 20.1 bn · 9.0% CAGR
- Metered Dose InhalerUSD 17.9 bn · 5.0% CAGR
- Surgical RoboticsUSD 17.7 bn · 14.0% CAGR
- Fill FinishUSD 17.6 bn · 9.0% CAGR
- SyringeUSD 21.2 bn · 6.5% CAGR